Cycloprodigiosin hydrochloride (cPrG-HCl), a member of the prodigiosin family of compounds, has been reported to act as an H þ /Cl À symporter. This compound induces apoptosis in several cancer cells and acts as an antitumor drug in animal models. In this study, we found a novel function of cPrG-HCl; to suppress cell death in PC12 cells, which is caused by protein synthesis inhibitors cycloheximide and actinomycin D. cPrG-HCl activated Akt and suppressed apoptosis, and this was accompanied by inhibition of caspase-3 activity and DNA fragmentation independently of its H þ /Cl À symporter activity. Wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, and dominant-negative Ras attenuated the anti-apoptotic activity of cPrG-HCl, which indicates that cPrG-HCl activated the Ras-PI3K-Akt pathway suppressing apoptosis. On the other hand, serum-deprivation-induced apoptosis was not suppressed by cPrG-HCl.
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Key words: Akt; apoptosis; prodigiosin; PC12 cells; Ras Apoptosis is a form of cell death characterized by cellular shrinkage, chromatin condensation, and nuclear fragmentation; this process occurs during development and inflammatory responses and is also induced by antitumor drugs or by irradiation with -rays. [1] [2] [3] In addition to these antitumor treatments, protein synthesis inhibitors and deprivation of trophic factors trigger apoptosis. [4] [5] [6] [7] During apoptosis, a group of cysteine proteases termed caspases are specifically activated, degrade substrates and induce DNA fragmentation. 8, 9) The clonal rat pheochromocytoma cell line PC12 is a well-studied model for neuronal cell death, in which stress and serum deprivation in the medium induce apoptosis. 5, 6) Neurotropic factors, such as nerve growth factor (NGF), effectively suppress apoptosis through binding to TrkA, an NGF receptor, which activates Ras and then stimulates phosphatidylinositol 3-kinase (PI3K), which leads to activation of Akt, a serine/threonine kinase that acts as a suppressor of apoptosis. 6, 10) Cycloprodigiosin hydrochloride (cPrG-HCl) is a red pigment produced by the marine bacterium Pseudoalteromonas denitrificans.
11) cPrG-HCl, as well as other prodigiosins, act as H þ /Cl À symporters that mediate movement of H þ ions along with Cl À ions through biological membranes including the plasma membrane. 12) Thus, cPrG-HCl induces acidification of the cytoplasm, since Cl À ions are generally less abundant in the cytoplasm than in the extracellular milieu. cPrGHCl, as well as other compounds of the prodigiosin family, induces apoptosis in various cancer cell lines both in vitro and in vivo. [13] [14] [15] [16] Previously, we have shown that cPrG-HCl induces apoptosis in various types of cancer cells by acidification of the cytoplasm, depending on the intrinsic nature of the H þ /Cl À symporter. 13, 14) However, recent studies have revealed that the biological effects of cPrG-HCl are not only due to its H þ /Cl À symporter activity. For example, cPrGHCl suppresses activation of NF-B and AP-1, transcription factors involved in cell survival and proliferation, through unknown mechanisms unrelated to H þ / Cl À symporter activity. 17, 18) We found here for the first time that cPrG-HCl has survival-promoting effects in PC12 cells. cPrG-HCl activates the Ras-PI3K-Akt pathway and suppresses y To whom correspondence should be addressed. Present address: Department of Molecular Oncology, Institute of Gerontology, Nippon Medical School, Kanagawa 211-8533, Japan; Fax: +81-44-733-1294; E-mail: kawauchi@nms.ac.jp stress-induced caspase-3 activity and apoptosis. The anti-apoptotic effects of cPrG-HCl are not related to its cytosol acidification activity.
Materials and Methods
Cell culture and materials. PC12 cells and PC12-RasN17 cells 4) were cultured in Dulbecco's modified Eagle's medium containing 10% horse serum, 5% fetal bovine serum, and 50 mg/ml kanamycin. NGF, forskolin and wortmannin were obtained from Sigma-Aldrich (St. Louis, Mo). Cycloheximide (CHX) and actinomycin D (ACT-D) were obtained from Nacalai Tesque (Kyoto, Japan). cPrG-HCl was prepared as described previously.
11)
Cell viability and assay for DNA fragmentation. Cell viability was determined by dye exclusion assay using a 0.1% trypan blue solution. DNA fragmentation was analyzed as described previously. 11) Briefly, cells were solubilized in buffer (10 mM Tris pH 7.4, 20 mM EDTA, 0.5% Triton X-100) on ice for 20 min, and centrifuged at 20 000 g for 20 min at 4 C. Supernatant-excluded genomic DNA was treated with phenol/chloroform, and cleaved DNA was recovered by ethanol precipitation. Soluble DNA (20 mg) was subjected to electrophoresis on an agarose gel containing ethidium bromide.
Assay of caspase-3 activity. Cells were disrupted by freeze-thawing in an extraction buffer (50 mM Tris pH 7.4, 1 mM EGTA, 5 mM EDTA, 5 mM MgCl 2 , 1 mM APMSF, 10 mg/ml pepstatin, 10 mg/ml leupeptin, and 1 mM DTT). Then, the suspension was centrifuged at 20 000 g for 20 min at 4 C, and the supernatant was incubated at 37 C for 1 h in a reaction buffer (50 mM Tris pH 7.4, 1 mM EDTA, and 10 mM EGTA) with 20 mM of the fluorogenic substrate DEVD-AFC (Peptide Institute, Osaka, Japan). Cleavage of the substrate was quantified by measuring the fluorescence of the released 7-amino-4-trifluomethyl coumarin by using a spectrofluorometer (Shimadzu RF5000, Kyoto, Japan) with excitation at 380 nm and emission at 460 nm.
Immunoblot analysis. Cell extracts were prepared as described previously.
17) The extracts were subjected to SDS-PAGE and transferred to an ECL membrane (Amersham Bioscience, Piscataway, NJ). Anti-phospho Akt Ser473 (Cell Signaling Technology, Beverly, MA) and anti-Akt (Cell Signaling Technology, Beverly, MA) antibodies were used in immunoblot analysis.
Results

cPrG-HCl suppresses CHX-or ACT-D-induced apoptosis in PC12 cells
Inhibition of protein synthesis by CHX or ACT-D induces cell death in PC12 cells. 4) To elucidate the effect of cPrG-HCl on stress-induced neuronal cell death, PC12 cells were cultured in the presence of CHX or ACT-D. Cell death was induced after incubation and cell viability reached <50% at 24 h (Fig. 1A, left) . Notably, cPrG-HCl restored cell viability to >70%. Consistently with survival-promoting activity, cPrG-HCl inhibited CHX-or ACT-D-induced DNA fragmentation in a dosedependent manner (Fig. 1B , left and middle). However, at a high concentration of 10 mM, cPrG-HCl did not suppress CHX-or ACT-D-induced apoptosis but increased it (data not shown). cPrG-HCl failed to suppress serum-deprivation-induced DNA fragmentation ( Fig. 1A and B, right). In contrast, NGF effectively suppressed DNA fragmentation caused by both serum deprivation and protein synthesis inhibitors. cPrG-HCl did not suppress CHX-or ACT-D-induced apoptosis in Jurkat cells (Fig. 1A, right) . Thus, the anti-apoptotic activity of cPrG-HCl appears to be specific to PC12 cells. cPrGHCl did not change the inhibitory effects of CHX and ACT-D on protein synthesis (data not shown).
cPrG-HCl suppresses caspase-3 activity in PC12 cells
Among caspases, activated caspase-3 cleaves many cellular proteins and leads to neuronal cell death. 6) To A, PC12 (left) or Jurkat (right) cells were pretreated with or without cPrG-HCl (1 mM) for 1 h and cultured in the presence or absence of CHX (10 mg/ml), ACT-D (1 mg/ml) or in serum-free medium (SF) for 24 h. The viable cells were counted using a trypan blue exclusion assay. The viable cell numbers when culturing in the presence of serum was estimated to be 100%. Bars show the SD of three independent assays. B, PC12 cells were pretreated with or without cPrG-HCl (0.1, 0.3 or 1 mM) for 1 h and cultured for 18 h in the presence of CHX (left) or ACT-D (middle), or in a serum-free medium (right). Soluble DNA was extracted from the cell, and the DNA samples were analyzed by electrophoresis on an agarose gel.
examine the effect of cPrG-HCl on caspase-3, we prepared lysates from PC12 cells treated with protein synthesis inhibitors or cultured in the absence of serum, and evaluated their activity in cleaving the synthetic peptide DEVD, a specific substrate of caspase-3. As shown in Fig. 2A , cPrG-HCl and NGF suppressed CHXor ACT-D-induced caspase-3 activity. Since cPrG-HCl failed to inhibit CHX-induced caspase-3 activity in Jurkat, HL-60, MKN45 and HeLa cells (Fig. 2D) , its inhibitory effect appears to be specific to PC12 cells. Although cPrG-HCl failed to inhibit serum-deprivationinduced apoptosis, it markedly suppressed caspase-3 activity in these cells (compare Figs. 1A and 2B ). These observations indicate that inhibition of caspase-3 is necessary and sufficient for suppression of proteinsynthesis-inhibition-induced apoptosis, but is not sufficient for serum-deprivation-induced apoptosis.
Since cPrG-HCl is an H þ /Cl À symporter, we investigated whether its intracellular acidification by cPrGHCl contributed to its antiapoptotic activity. As shown in Fig. 2C , cPrG-HCl suppressed CHX-induced caspase-3 activity in the presence of cell-permeable weak base imidazole, which inhibited cPrG-HCl-induced intracellular acidification. In addition, the V-ATPase inhibitor bafilomycin, which also induces intracellular acidification, failed to suppress caspase-3 activity ( Fig. 2A and  B) . Bafilomycin did not suppress CHX-and ACT-D-induced DNA fragmentation (data not shown). Thus, the inhibitory effect of cPrG-HCl on caspase-3 activity is independent of its H þ /Cl À symporter activity.
Wortmannin reverses the survival effects of cPrG-HCl NGF suppresses apoptosis in neuronal cells through activation of PI3K and Akt, 6) while forskolin suppresses apoptosis via the production of cAMP, which activates protein kinase A (PKA). 4, 19) We examined whether cPrG-HCl suppressed protein-synthesis-inhibition-induced apoptosis through the PI3K-Akt pathway or the c-AMP-PKA pathway. As shown in Fig. 3A , cPrG-HCl and NGF induced phosphorylation of Akt. Wortmannin, an inhibitor PI3K, reversed both cPrG-HCl-and NGFtriggered phosphorylation of Akt, which indicated that cPrG-HCl activated Akt through PI3K. Furthermore, cPrG-HCl and NGF failed to suppress DNA fragmentation and caspase-3 activity in the presence of wortmannin when cells were treated with protein synthesis inhibitors ( Fig. 3B and C) . Suppression of caspase-3 activity by cPrG-HCl was attenuated by another PI3K inhibitor LY294002 (data not shown). In contrast, wortmannin did not abrogate the forskolin-mediated suppression of DNA fragmentation and caspase-3 activity (Fig. 3B and C) . cPrG-HCl activated the PI3K-Akt signaling pathway suppressing caspase-3 activity and apoptosis.
cPrG-HCl suppresses protein synthesis inhibitioninduced apoptosis through Ras
Binding of NGF to its receptor, TrkA, activates Ras, which in turn triggers stimulation of the PI3K-Akt pathway. 6, 10) It is known that activation of the Ras-PI3K-Akt pathway is essential for NGF to suppress apoptosis. Indeed, we have observed that NGF fails to suppress apoptosis in a PC12 cell line expressing a dominant negative Ras mutant, RasN17 (PC12-RasN17 cells). 4) To determine whether cPrG-HCl suppressed apoptosis through the Ras-PI3K-Akt pathway, PC12-RasN17 cells were cultured in the presence of protein synthesis inhibitors. NGF and cPrG-HCl failed to attenuate CHX-, ACT-D-induced cell death, DNA fragmentation and caspase-3 activity in PC12-RasN17 A, PC12 cells were pretreated with or without wortmannin (10 mM) for 1 h and cultured in cPrG-HCl (1 mM) for 1 h or NGF for 30 min. Phosphorylated Akt was determined by immunoblot analysis using an anti-phospho-Akt antibody. B, PC12 cells were pretreated with or without wortmannin for 1 h and treated with or without cPrG-HCl, NGF or forskolin (10 mM) for 1 h. Cells were cultured with CHX (left) or ACT-D (right). After incubation for 18 h, soluble DNA was extracted from the cells, and DNA samples were analyzed by electrophoresis on an agarose gel. C, PC12 cells were pretreated with or without wortmannin for 1 h and treated with or without cPrG-HCl, NGF or forskolin (10 mM) for 1 h. Cells were cultured with CHX (left) or ACT-D (right). After incubation for 8 h, caspase-3 activity in cell extracts was measured using DEVD-AFC. The activity of non-treated cells was set to 1. Bars show the SD of three independent assays. cell line (Fig. 4A-C) . In contrast, forskolin effectively suppressed these apoptotic responses in RasN17-PC12 and PC12 cells. These results indicate that cPrG-HCl suppresses the apoptosis through the Ras-PI3K-Akt pathway.
Discussion cPrG-HCl acts as an antitumor drug in mouse models by its ability to induce apoptosis. 13 ) However, we found that cPrG-HCl effectively rescued PC12 cells from CHX-or ACT-D-induced apoptosis. This was not a surprising result because several agents have the ability to induce and to inhibit apoptosis in cell-type and deathstimulus specific manners. For example, while protein synthesis inhibitors protect neuronally differentiated PC12 cells from apoptosis induced by deprivation of neurotrophic factors, these inhibitors promote apoptosis in naive PC12 cells. In addition, cPrG-HCl suppressed apoptosis induced by protein synthesis inhibitors but promoted apoptosis by serum deprivation in PC12 cells (Fig. 1A) .
The failure of cPrG-HCl to prevent apoptosis in PC12-RasN17 cells clearly indicates that cPrG-HCl suppresses apoptosis through Ras. The mechanism by which cPrG-HCl activates the Ras-PI3K-Akt pathway and suppresses apoptosis is unclear, but there are several plausible explanations. One is that changes in intracellular pH by cPrG-HCl activate Ras and stimulate the Ras-PI3K-Akt pathway. Indeed, it has been reported that Ras is activated by sustained intracellular acidification. 20) However, cPrG-HCl suppressed caspase-3 activity in the presence of imidazole, which blocks intracellular acidification (Fig. 2C) . Furthermore, bafilomycin, which also induces acidification of cytoplasm, failed to prevent apoptosis. Thus, activation of Ras by intracellular acidification, if any, is not sufficient to suppress apoptosis.
Another explanation is that cPrG-HCl stimulates proteins upstream of the Ras-PI3K-Akt pathway, including the NGF receptor TrkA, and many signaling components such as Grb2, Shc, and Sos. cPrG-HCl is a hydrophobic compound that can be incorporated into the lipid bilayer of the plasma membrane, in which TrkA, Grb2, Shc, Sos and Ras are activated. If cPrG-HCl activates these proteins, it is possible that activated upstream signaling components stimulate the Ras-PI3K-Akt pathway and other signaling pathways, and then prevent apoptosis.
NGF also activates Ras, PI3K and Akt to suppress apoptosis. An apparent difference is that, while cPrGHCl does not inhibit apoptosis induced by serum deprivation, NGF protects PC12 cells from apoptosis induced either by protein synthesis inhibitors or by serum deprivation. This discrepancy may be due to a property of cPrG-HCl that triggers several cellular responses that lead to apoptosis, concurrent with activation of the Ras-PI3K-Akt pathway.
First, cPrG-HCl induces acidification of the cytoplasm as described above. Changes in cellular pH perturb metabolism and homeostasis that are essential for cell life and trigger an apoptotic response.
Secondly, cPrG-HCl acts as a genotoxic drug that damages DNA and triggers p53-mediated apoptotic responses. 21) DNA damage activates p53, a transcription factor that induces the expression of many pro-apoptotic genes. It has been reported that protein synthesis inhibitors partially suppress p53-mediated apoptosis by suppression of apoptotic gene expression. 22) If cPrGHCl activates p53 in PC12 cells, CHX and ACT-D might suppress apoptosis by inhibition of pro-apoptotic gene expression. Thus, it is plausible that cPrG-HCl promotes cell survival through activation of the Ras-PI3K-Akt pathway when protein synthesis inhibitors suppress p53-mediated pro-apoptotic gene expression. Consistently with this scenario, cPrG-HCl did not suppress, but rather promoted, CHX-and ACT-Dinduced apoptosis in Jurkat, HL60, MKN45 and HeLa cells, all which are malignant tumor cells that lack functional p53.
Thirdly, cPrG-HCl suppresses activation of NF-B, an important transcription factor that leads to expression of anti-apoptotic genes. 23) Thus, cPrG-HCl-induced suppression of NF-B renders cells susceptible to apoptosis. Indeed, cPrG-HCl progressively enhances TNF-induced apoptosis by suppressing the transcriptional activity of NF-B. 17) Since the suppression of NF-B activity induces sustained JNK activity, which leads to apoptosis, [24] [25] [26] cPrG-HCl might promote cell death through sustained activation of JNK, accompanied by suppression of NF-B. We found that cPrG-HCl suppressed NF-B activation in PC12 cells and led to sustained JNK activity (data not shown). cPrG-HCl generated anti-apoptotic signals through stimulation of the Ras-PI3K-Akt pathway, but it could not overcome pro-apoptotic responses triggered by cPrG-HCl itself, including acidification of the cytoplasm, DNA damage, suppression of NF-B, and sustained JNK activity.
Caspases are important proteases that induce apoptosis, but not all cell death depends on them. It has been reported that caspase-2 processing is required for cell death under conditions of serum deprivation. 7, 27, 28) Consistently with this, caspases are activated in PC12 cells in serum-free medium, and a caspase inhibitor z-VAD effectively suppressed apoptosis. However, z-VAD failed to suppress apoptosis induced by serum deprivation in the presence of cPrG-HCl (data not shown). In other words, z-VAD did not suppress cPrGHCl-induced apoptotic responses, which suggests that cPrG-HCl triggers cell death independent of caspase activation.
cPrG-HCl acts as anticancer agent; however, it should be noted that its cytotoxicity differs depending on the cell type and conditions. For example, its IC 50 for the human liver cancer cell line HuH-7 is 272 nM, while that for isolated normal rat hepatocytes and PC12 cells is 8.4 mM and >10 mM, respectively. 13, 29) The difference in its cytotoxicity may be caused by the characteristics of the target cells.
Considering our new findings that cPrG-HCl exhibits a protective effect against cell death in PC12 cells, combined application of cPrG-HCl and other anticancer drugs such as ACT-D might specifically induce apoptosis in harmful targets (e.g., cancer cells), while they protect intact cells from unwanted apoptosis. However, it is not possible to use cPrG-HCl in its current state because its H þ /Cl À symporter activity obstructs neuronal cell function. A phase I/II clinical trial of a prodigiosin derivative that retains its high antitumor activity and has attenuated toxicity has been conducted. 15) Our results provide a potential new strategy for combined chemotherapy using prodigiosin derivatives.
